HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a developer of generic and specialty drugs for the treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for treating dry eye diseases; HL189 against non-infectious uveitis; IM156 targeting cancers; and HL190 to treat wet age-related macular degeneration. It also sells drugs for treating digestive dysfunction, osteoporosis, liver dysfunction, hepatic coma, metabolic disorders caused due to hypocalcemia, tetania, bone pain and also bone lesions. HanAll also conducts research for developing drugs in the therapeutic areas of autoimmune, eye diseases and immuno oncology indications. The company partners with global pharmaceutical companies and academic institutions for advancing its pipeline products. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea
Headquarters
South Korea
Address
43, Sangseodang 1-Gil, Daedeok-Gu, Daejeon, Seoul, 34344
Website
www.hanallbiopharma.com
Telephone
82 42 9325997
No of Employees
408
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
009420 (KRX)
Revenue (2022)
$103.3M
22.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
1295.2%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
1,030.4%
(2022 vs 2021)
* As of and is in US$
HanAll Biopharma Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| HL036 - Dry Eye Diseases |
| HL189 - Non-Infectious Uveitis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Financing Agreements | In July, the company and Daewoong Pharmaceutical co-invested in Vincere Biosciences. |
| 2023 | Contracts/Agreements | In May, the company along with Daewoong Pharmaceutical entered into a joint research and development agreement with NurrOn Pharmaceuticals to develop treatments for Parkinson's disease and other neurodegenerative diseases. |
| 2023 | Financing Agreements | In February, the company invested in Interon Laboratories, Inc., a biotechnology company. |
Competitor Comparison
| Key Parameters | HanAll Biopharma Co Ltd | Daewoong Pharmaceutical Co Ltd | Huons Global Co Ltd | DAE HWA Pharmaceutical Co Ltd | Ilsung Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Daejeon | Hwaseong | Seongnam | Hoengseong | Seoul |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 408 | 1,256 | 541 | 424 | 236 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jae Chun Yoon | Chairman | Executive Board | - | - |
| Park Soo-jin | Director; Co-Chief Executive Officer | Executive Board | 2023 | - |
| Sean (Seungwon) Jeong | President; Chief Executive Officer | Senior Management | - | - |
| Su Jin Park | Vice President; Chief Executive Officer | Senior Management | - | - |
| Cheol Hun Lee | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward